Sinclair Pharma plc
Result of 2017 Annual General Meeting
At the Annual General Meeting of Sinclair Pharma plc (the “Company”) held on Wednesday 26 April
2017 all of the resolutions set out in the notice of annual general meeting posted with the Annual
Report of the Company and dated 31 March 2017, were duly passed by the requisite majority without
amendment.
A breakdown of the proxies lodged prior to the Annual General Meeting in respect of each resolution
is summarised below:
For
Third Party
Against
Discretion
Withheld
Resolution 1
To receive and adopt the Financial
Statements and the Directors’ and
Auditors’ Report for the 18 months
ended 31 December 2016
347,086,560
3,583,954
617
0
Resolution 2
To re-elect Chris Spooner as a Director
343,139,665
3,584,982
3,945,484
1,000
Resolution 3
To elect Alan Olby as a Director
343,139,203
3,584,982
3,945,390
1,556
Resolution 4
To re-appoint PricewaterhouseCoopers
LLP as auditors
345,870,618
3,583,806
1,216,151
556
Resolution 5
To authorise the Directors to determine
the auditors remuneration
To approve the Directors’ remuneration
report for the period ended 31
December 2016
To authorise the Directors to allot equity
securities
345,865,696
,3583,806
1,220,609
1,020
269,690,792
3,584,571
77,388,378
7,390
327,791,729
3,701,323
1,268,484
17,909,595
To disapply the statutory pre-emption
rights
329,000,326
3,701,323
58,850
17,910,632
Resolution 6
Resolution 7
Resolution 8
Notes:
1. Any proxy arrangements which gave discretion to the Chairman have been included in the "For"
totals.
2. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of
votes "for" or "against" a resolution.
3. The total number of valid proxy appointments and associated voting instructions received prior to
the Annual General Meeting was 136.
4. The share capital of the Company as at 31 March 2017 was 503,768,952 ordinary shares.